NBIX Neurocrine Biosciences, Inc.
$145.87▲ +2.22%
Healthcare
Other
Volume 1.28M
Avg Volume (10D) 1.23M
Key Metrics & Fundamentals
Market Cap
$14.83B
P/E Ratio
21.4
Div Yield
0.00%
52W Range
122.14 - 186.12
% vs 50 MA
-0.97%
% vs 200 MA
-0.86%
RSI-14
55.4
MACD Histogram
+1.2300
Beta (1Y vs SPY)
0.60
Free Cash Flow
$128.60M
Gross Rev
$959.00M
Gross Profit
$935.80M
EBITDA
$177.80M
COGS
$23.20M
Operating Exp
$782.80M
Operating Income
$153.00M
EBIT
$153.00M
Pretax Income
$162.20M
Net Income
$144.40M
EPS (Diluted)
1.39
Price & Volume History
Loading chart…
Recent News
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Zacks · Oct 26, 2026 9:00 AM ET
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
PR Newswire · Oct 26, 2026 8:30 AM ET
Where Will Neurocrine Biosciences Be in 5 Years?
Motley Fool · Oct 25, 2026 7:05 AM ET
Expert Publication On PWS Treatment Could Be A Game Changer For Neurocrine Biosciences (NBIX)
Simply Wall St. · Oct 24, 2026 1:16 AM ET
Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Trial
Simply Wall St. · Oct 23, 2026 3:11 AM ET
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
PR Newswire · Oct 22, 2026 4:05 PM ET
Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease
MT Newswires · Oct 20, 2026 9:31 AM ET
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
PR Newswire · Oct 20, 2026 8:30 AM ET
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating
MT Newswires · Oct 19, 2026 7:17 AM ET
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings
Simply Wall St. · Oct 16, 2026 7:16 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See NBIX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.